Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ACAD

Acadia Pharmaceuticals Inc

Apr 17 • 04:00PM ET

17.19

Dollar change +0.11
Percentage change 0.64	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB IWM VXF VBK FBT IBB IWO SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.38	Insider Own	0.80%	Shs Outstand	164.65M	Perf Week	-3.05%
Market Cap	2.83B	Forward P/E	13.56	EPS next Y	1.27	Insider Trans	-6.29%	Shs Float	163.46M	Perf Month	-8.17%
Income	-61.29M	PEG	-	EPS next Q	0.06	Inst Own	97.03%	Short Float	6.85%	Perf Quarter	-38.56%
Sales	726.44M	P/S	3.90	EPS this Y	277.17%	Inst Trans	0.91%	Short Ratio	6.24	Perf Half Y	-27.71%
Book/sh	2.62	P/B	6.56	EPS next Y	93.44%	ROA	-9.17%	Short Interest	11.20M	Perf Year	-11.25%
Cash/sh	2.66	P/C	6.45	EPS next 5Y	-	ROE	-14.73%	52W Range	16.60 - 33.99	Perf YTD	-45.10%
Dividend Est.	-	P/FCF	170.11	EPS past 5Y	28.03%	ROI	-12.78%	52W High	-49.43%	Beta	0.41
Dividend TTM	-	Quick Ratio	2.28	Sales past 5Y	27.73%	Gross Margin	94.27%	52W Low	3.55%	ATR (14)	0.67
Dividend Ex-Date	-	Current Ratio	2.42	EPS Y/Y TTM	71.78%	Oper. Margin	-10.10%	RSI (14)	30.74	Volatility	3.22% 2.85%
Employees	598	Debt/Eq	0.13	Sales Y/Y TTM	40.45%	Profit Margin	-8.44%	Recom	1.75	Target Price	29.17
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	206.75%	Payout	-	Rel Volume	0.57	Prev Close	17.08
Sales Surprise	3.24%	EPS Surprise	-3.08%	Sales Q/Q	69.27%	Earnings	Feb 27 AMC	Avg Volume	1.79M	Price	17.19
SMA20	-4.26%	SMA50	-20.07%	SMA200	-30.74%	Trades		Volume	1,027,814	Change	0.64%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-12-24	Reiterated	Needham	Buy	$36 → $32
Mar-12-24	Downgrade	Mizuho	Buy → Neutral	$39 → $25
Jan-30-24	Initiated	Robert W. Baird	Outperform	$40
Jan-24-24	Upgrade	Needham	Hold → Buy	$37
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$31 → $40
Dec-14-23	Downgrade	Deutsche Bank	Buy → Hold	$25
Dec-13-23	Initiated	Citigroup	Buy	$38
Dec-12-23	Initiated	Deutsche Bank	Buy	$25
Nov-06-23	Upgrade	Mizuho	Neutral → Buy	$20 → $35
Oct-17-23	Initiated	UBS	Buy	$33
Oct-10-23	Upgrade	JP Morgan	Neutral → Overweight	$29 → $32
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy	$22
Nov-04-22	Downgrade	Goldman	Neutral → Sell	$15 → $12
Nov-01-22	Initiated	Loop Capital	Hold	$17
Aug-08-22	Downgrade	Citigroup	Buy → Neutral	$19 → $15
Aug-05-22	Downgrade	Citigroup	Buy → Neutral	$19 → $15
Jun-21-22	Downgrade	Jefferies	Buy → Underperform	$25 → $10
Jun-16-22	Upgrade	Jefferies	Hold → Buy	$25
Mar-16-22	Upgrade	Canaccord Genuity	Hold → Buy	$30 → $31
Feb-09-22	Upgrade	H.C. Wainwright	Neutral → Buy	$36

Show Previous Ratings

Apr-17-24 04:05PM	Acadia Pharmaceuticals Presents New DAYBUE (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting (Business Wire)
Apr-11-24 02:10PM	3 Pharma Stocks to Sell in April Before They Crash & Burn (InvestorPlace)
Apr-10-24 01:28AM	ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares (GuruFocus.com)
Apr-02-24 04:05PM	Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development (Business Wire)
Apr-01-24 04:05PM	Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
11:30AM	Loading…
Mar-28-24 11:30AM	Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report? (Zacks)
02:00AM	ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 17,714 Shares (GuruFocus.com)
Mar-20-24 01:31PM	Billionaire Steve Cohen and Insiders are Buying These 5 Stocks (Insider Monkey)
Mar-15-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-14-24 06:49PM	3 Pharma Stocks to Sell in March Before They Crash & Burn (InvestorPlace)
Mar-13-24 04:05PM	Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day (Business Wire)
Mar-12-24 04:08PM	Acadia Hits 11-Month Low After Outsized Placebo Effect Torpedoes Schizophrenia Study (Investor's Business Daily) -17.20%
03:05PM	Acadia Pharmaceuticals Stock Sinks After Schizophrenia Drug Study Falls Short (Investopedia)
11:06AM	Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails (Zacks)
09:30AM	Why Is Acadia Pharmaceuticals (ACAD) Stock Down 18% Today? (InvestorPlace)
07:43AM	Loading…
07:43AM	5 Things to Know Before the Stock Market Opens (Investopedia)
Mar-11-24 04:46PM	UPDATE 2-Acadia to stop trials of antipsychotic drug after it fails schizophrenia study (Reuters)
04:13PM	Acadia Pharmaceuticals' schizophrenia drug fails in late-stage study (Reuters)
04:05PM	Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia (Business Wire)
Feb-29-24 09:05AM	Acadia Pharmaceuticals to Participate in TD Cowens 44th Annual Health Care Conference on March 6, 2024 (Business Wire)
08:44AM	ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 04:05PM	Acadia Stock Dives As Unexpected Seasonality Rocks Its Most High-Profile Launch (Investor's Business Daily) -9.92%
09:12AM	Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down (Zacks)
Feb-27-24 05:20PM	Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Zacks)
04:56PM	ACADIA Pharmaceuticals Inc. Reports Strong Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
04:27PM	Acadia: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview (Business Wire)
Feb-22-24 08:16PM	ACADIA Pharmaceuticals Inc. Investors: Please contact the Portnoy Law Firm to recover your losses (GlobeNewswire)
Feb-21-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-20-24 10:00AM	Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy? (Zacks)
04:05PM	Loading…
Feb-13-24 04:05PM	Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 (Business Wire)
Feb-08-24 01:15PM	The 3 Most Undervalued Biotech Stocks to Buy in February 2024 (InvestorPlace)
Jan-30-24 08:48PM	Acadia Announces Additions to Executive Team (Business Wire)
05:00PM	20 Countries With The Highest Number of Drug Trafficking in the World (Insider Monkey)
Jan-26-24 05:31PM	Best Drug and Alcohol Rehab Centers in Each of 30 Biggest Cities in the US (Insider Monkey)
Jan-25-24 08:42AM	10 Stocks Receiving a Massive Vote of Approval From Wall Street Analysts (Insider Monkey)
Jan-19-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-18-24 04:05PM	Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic (Business Wire)
Jan-12-24 05:02PM	ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 3,732 Shares (GuruFocus.com)
Dec-21-23 04:05PM	Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 (Business Wire)
Dec-18-23 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-13-23 09:24PM	Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID (pimavanserin) (Business Wire) +34.48%
04:14PM	Acadia Soars To A Four-Month High After Winning A Patent Battle For Its Biggest Drug (Investor's Business Daily)
01:41PM	Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID (pimavanserin) Patent Litigation (Business Wire)
Nov-30-23 09:05AM	Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome (Business Wire)
Nov-27-23 09:05AM	Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimers Disease Psychosis (Business Wire)
Nov-21-23 11:03PM	Insider Sell Alert: EVP Brendan Teehan Sells Shares of ACADIA Pharmaceuticals Inc (GuruFocus.com)
05:00PM	Acadia Pharmaceuticals Announces Change in Research and Development Leadership (Business Wire)
Nov-17-23 09:40AM	Are Medical Stocks Lagging ACADIA Pharmaceuticals (ACAD) This Year? (Zacks)
Nov-16-23 08:42AM	Implied Volatility Surging for On ACADIA Pharmaceuticals (ACAD) Stock Options (Zacks)
Nov-14-23 04:12PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-08-23 05:24PM	3 Biotech Stocks With the Strongest Clinical Pipelines (InvestorPlace)
Nov-04-23 01:10PM	ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 06:51PM	ACADIA Pharmaceuticals Inc. Reports Record Revenues in Q3 2023 (GuruFocus.com)
04:37PM	Acadia: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview (Business Wire)
Oct-31-23 04:05PM	Acadia Pharmaceuticals to Participate in the Guggenheim Securities 5th Annual Inflammation & Immunology Conference (Business Wire)
Oct-26-23 10:02AM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-23-23 09:05AM	Acadia Pharmaceuticals Announces the Rett Sibling Scholarship Program (Business Wire)
Oct-19-23 04:05PM	Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023 (Business Wire)
Oct-18-23 05:00PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-10-23 10:49AM	Why Acadia Pharmaceuticals Stock Is Rising Today (Motley Fool) +7.73%
09:32AM	Rivian upgraded, Qorvo downgraded: Wall Street's top analyst calls (The Fly)
Oct-07-23 05:01AM	EVP, General Counsel, Secretary Austin Kim Sells 16,369 Shares of ACADIA Pharmaceuticals Inc (GuruFocus.com)
Sep-30-23 10:30AM	2 Growth Stocks I'd Buy on the Dip (Motley Fool)
Sep-22-23 06:23PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-19-23 04:05PM	Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications (Business Wire)
Aug-30-23 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
Aug-28-23 06:00PM	2 Supercharged Growth Stocks Billionaires Can't Stop Buying (Motley Fool)
Aug-22-23 08:30AM	Can This Red-Hot Biotech Stock Keep Beating the Broader Markets? (Motley Fool)
Aug-19-23 10:44AM	Billionaire Stan Druckenmillers Small-Cap Stock Picks (Insider Monkey)
Aug-14-23 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-04-23 12:36PM	Puma Biotech (PBYI) Q2 Earnings Beat, Nerlynx Sales Outperform (Zacks)
Aug-02-23 04:26PM	Acadia: Q2 Earnings Snapshot (AP Finance)
04:05PM	Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview (Business Wire)
Aug-01-23 07:30PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-25-23 11:21AM	Biogen (BIIB) Beats on Q2 Earnings & Sales, Announces Job Cuts (Zacks)
Jul-24-23 04:05PM	Acadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D., as Senior Vice President, Chief Business Officer (Business Wire)
Jul-21-23 09:40AM	Is ACADIA Pharmaceuticals (ACAD) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-19-23 04:04PM	Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 2, 2023 (Business Wire)
Jul-15-23 08:19AM	Analysts Just Published A Bright New Outlook For ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) (Simply Wall St.)
Jul-14-23 04:04PM	Acadia's Newest Drug Just Obliterated Sales Expectations; Shares Hit Two-Year High (Investor's Business Daily) +24.73%
11:41AM	Why Acadia Pharmaceuticals Stock Is Soaring Today (Motley Fool)
Jul-13-23 07:11PM	Why These 2 Biotech Stocks Made Big Moves Late Thursday (Motley Fool)
04:05PM	Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neurens NNZ-2591 in Rett Syndrome and Fragile X Syndrome (Business Wire)
Jun-26-23 05:00PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-13-23 04:05PM	Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome (Business Wire)
Jun-12-23 01:24PM	ACADIA Pharmaceuticals (NASDAQ:ACAD) delivers shareholders favorable 9.3% CAGR over 5 years, surging 3.1% in the last week alone (Simply Wall St.)
Jun-08-23 11:10AM	Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER Study Evaluating DAYBUE (trofinetide) Efficacy and Safety in Patients with Rett Syndrome (Business Wire)
Jun-07-23 11:30AM	Acadia (ACAD) Up 12% Since Last Earnings Report: Can It Continue? (Zacks)
05:58AM	3 Penny Stocks That Could Skyrocket in the Next 12 Months (InvestorPlace)
Jun-01-23 09:04AM	Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-08-23 05:25PM	Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:13PM	Acadia: Q1 Earnings Snapshot (AP Finance)
04:05PM	Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview (Business Wire)
09:21AM	ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Is Matching Sentiment Around Its Revenues (Simply Wall St.)
May-05-23 04:04PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-02-23 09:04AM	Acadia Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Apr-25-23 09:04AM	Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023 (Business Wire)
Apr-20-23 09:04AM	Acadia Pharmaceuticals to Present DAYBUE (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting (Business Wire)

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DAVIS STEPHEN	CEO	Apr 08 '24	Sale	17.87	26,574	474,877	144,267	Apr 09 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Apr 08 '24	Sale	17.87	2,716	48,535	28,742	Apr 09 06:00 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Apr 08 '24	Sale	17.87	2,568	45,890	38,796	Apr 09 06:00 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Apr 08 '24	Sale	17.87	1,790	31,987	13,100	Apr 09 06:00 PM
DAVIS STEPHEN	CEO	Mar 27 '24	Sale	17.90	17,714	317,081	118,842	Mar 27 07:58 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Mar 27 '24	Sale	17.90	5,434	97,269	26,183	Mar 27 07:57 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Mar 27 '24	Sale	17.90	5,140	92,006	36,340	Mar 27 08:00 PM
DAVIS STEPHEN	CEO	Feb 26 '24	Sale	24.67	5,577	137,585	101,890	Feb 27 06:02 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Feb 26 '24	Sale	24.67	772	19,045	21,067	Feb 27 06:13 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Feb 26 '24	Sale	24.67	624	15,394	31,432	Feb 27 06:10 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Feb 26 '24	Sale	24.67	474	11,694	11,391	Feb 27 06:07 PM
DAVIS STEPHEN	CEO	Jan 08 '24	Sale	29.96	3,732	111,811	96,521	Jan 09 06:00 PM
Teehan Brendan	EVP, COO, Head of Commercial	Jan 08 '24	Sale	29.96	731	21,901	30,949	Jan 09 06:00 PM
KIM AUSTIN D.	EVP,General Counsel, Secretary	Jan 08 '24	Sale	29.96	590	17,676	46,901	Jan 09 06:00 PM
Kihara James	Principal Accounting Officer	Dec 15 '23	Sale	28.30	2,000	56,600	11,025	Dec 15 07:37 PM
Schneyer Mark C.	EVP, Chief Financial Officer	Nov 20 '23	Sale	22.64	5,108	115,645	20,486	Nov 21 06:00 PM
Teehan Brendan	EVP, COO, Head of Commercial	Nov 20 '23	Sale	22.64	4,960	112,294	30,393	Nov 21 06:00 PM
Kihara James	Principal Accounting Officer	Nov 20 '23	Sale	22.64	1,985	44,940	13,025	Nov 21 06:00 PM
DAVIS STEPHEN	CEO	Oct 06 '23	Sale	21.96	51,563	1,132,323	89,131	Oct 06 09:59 PM
KIM AUSTIN D.	EVP,General Counsel, Secretary	Oct 06 '23	Sale	21.96	16,369	359,463	45,857	Oct 06 10:00 PM
Kihara James	Principal Accounting Officer	Sep 15 '23	Sale	25.88	2,000	51,760	10,778	Sep 19 06:31 PM
Schneyer Mark C.	EVP, Chief Financial Officer	Aug 21 '23	Sale	29.00	10,000	289,970	15,682	Aug 23 07:31 PM
DAVIS STEPHEN	CEO	Jul 14 '23	Option Exercise	20.77	100,000	2,077,000	136,695	Jul 18 06:00 PM
DAVIS STEPHEN	CEO	Jul 14 '23	Sale	30.04	100,000	3,004,350	36,695	Jul 18 06:00 PM
DAVIS STEPHEN	CEO	Jul 12 '23	Sale	25.05	55,104	1,380,449	36,695	Jul 13 08:27 PM
DAVIS STEPHEN	CEO	Jul 11 '23	Sale	25.00	16,498	412,450	91,799	Jul 13 08:27 PM
Kihara James	Principal Accounting Officer	Jun 15 '23	Sale	24.15	2,000	48,300	9,144	Jun 16 04:38 PM
Brege Laura	Director	Jun 12 '23	Sale	24.87	4,500	111,906	13,502	Jun 14 05:14 PM
Schneyer Mark C.	EVP, Chief Financial Officer	Jun 08 '23	Option Exercise	0.00	1,893	0	23,798	Jun 12 08:48 PM
Schneyer Mark C.	EVP, Chief Financial Officer	Jun 08 '23	Sale	25.02	974	24,369	22,824	Jun 12 08:48 PM
BAKER BROS. ADVISORS LP	Director	May 24 '23	Buy	25.48	553,263	14,096,825	39,317,673	May 24 05:09 PM
BAKER BROS. ADVISORS LP	Director	May 23 '23	Option Exercise	17.01	25,000	425,250	38,620,261	May 24 05:09 PM
BAKER BROS. ADVISORS LP	Director	May 23 '23	Buy	25.41	209,053	5,312,458	38,811,515	May 24 05:09 PM
BAKER BROS. ADVISORS LP	Director	May 22 '23	Buy	24.57	134,206	3,297,815	38,607,761	May 24 05:09 PM
Schneyer Mark C.	EVP, Chief Financial Officer	May 17 '23	Sale	22.50	15,310	344,475	21,905	May 19 06:48 PM
Teehan Brendan	EVP, COO, Head of Commercial	May 17 '23	Sale	22.50	14,869	334,552	24,356	May 19 06:43 PM
Kihara James	Principal Accounting Officer	May 17 '23	Sale	22.50	5,947	133,808	11,144	May 19 06:54 PM
DAVIS STEPHEN	CEO	May 01 '23	Sale	21.18	7,806	165,331	108,297	May 02 07:02 PM
KIM AUSTIN D.	EVP,General Counsel, Secretary	May 01 '23	Sale	21.18	917	19,422	25,513	May 02 07:06 PM
Teehan Brendan	EVP, COO, Head of Commercial	May 01 '23	Sale	21.18	548	11,607	9,487	May 02 07:04 PM
DAVIS STEPHEN	CEO	Apr 29 '23	Option Exercise	0.00	15,625	0	116,103	May 02 07:02 PM
Teehan Brendan	EVP, COO, Head of Commercial	Apr 29 '23	Option Exercise	0.00	1,567	0	10,035	May 02 07:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACAD

Acadia Pharmaceuticals Inc

Upgrade your FINVIZ experience